FibroBiologics to Present at the DealFlow Discovery Conference
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the DealFlow Discovery Conference in Atlantic City on January 28-29, 2026. The company presentation is scheduled for 11:30 a.m. ET on January 29, 2026. FibroBiologics is a clinical-stage biotechnology company focused on therapeutics using fibroblasts and fibroblast-derived materials and holds 270+ patents issued and pending. Management will be available for one-on-one investor meetings during the event and provided contact details for further information.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FBLG declined 3.70%, reflecting a moderate negative market reaction. This price movement removed approximately $877K from the company's valuation, bringing the market cap to $23M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
FBLG was down 0.77% pre-news. Peers showed mixed moves: GDTC up 5.93%, CRIS up 4.79% (but flagged down in momentum scanner separately), while ICU, LIXT, and NRXS were modestly negative. Only 1 peer appeared in the momentum scan, indicating stock-specific trading rather than a clear sector-wide pattern.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Shareholder update | Positive | +32.3% | Detailed 2025 progress, new lab, trials, financings and debt payoff. |
| Jan 06 | Conference presentation | Neutral | +6.8% | Announced CEO presentation at BFC Global healthcare investment conference. |
| Jan 05 | Preclinical data | Positive | +1.5% | Reported positive FSdC preclinical results in degenerative disc disease models. |
| Dec 31 | IND filing | Positive | -7.0% | Filed Phase 1/2 IND with FDA for CYPS317 in psoriasis. |
| Dec 16 | Equity offering | Negative | -8.4% | Closed $1.7M registered direct offering with associated warrants. |
Recent news has often aligned with price moves: positive clinical and corporate updates tended to see gains, while dilutive offerings saw declines. One notable divergence occurred when a positive IND filing was followed by a negative price reaction.
Over the last several weeks, FibroBiologics reported multiple financing transactions and important clinical and corporate milestones. On Dec 16, 2025, a registered direct offering led to a -8.44% move. A Dec 31, 2025 IND filing for CYPS317 in psoriasis saw a -7.03% reaction despite being a clinical advancement. In early January 2026, positive preclinical FSdC data and a shareholder letter outlining new facilities, trials, and financings supported gains up to 32.27%. Conference presentation announcements have previously coincided with moderate upside.
Market Pulse Summary
This announcement highlights FibroBiologics’ continued outreach to the investment community, adding another investor-focused presentation to a recent stream of clinical and financing updates. With the stock trading well below its $2.12 52-week high and under the $0.60 200-day MA, prior offerings and proxy proposals around capital structure remain important context. Investors may watch for future trial initiations, data readouts, and any additional financing or listing-related actions alongside these conference appearances.
Key Terms
clinical-stage medical
AI-generated analysis. Not financial advice.
HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the DealFlow Discovery Conference taking place January 28-29, 2026, at the Borgata in Atlantic City, New Jersey.
FibroBiologics will deliver a company presentation at 11:30 a.m. ET on Thursday, January 29 and will be available for one-on-one investor meetings throughout the event.
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When will FibroBiologics (FBLG) present at the DealFlow Discovery Conference?
Who from FibroBiologics will present at the January 2026 DealFlow Discovery Conference?
Where is the DealFlow Discovery Conference where FBLG will present?
How can investors schedule one-on-one meetings with FibroBiologics at the conference?
What is FibroBiologics' business focus mentioned for the January 2026 presentation?
